Cardiovascular disease is the leading cause of morbidity and death, with coronary heart disease accounting for 43% of deaths attributable to this condition in the US . A major modifiable risk factor for atherosclerotic cardiovascular disease is elevated serum low-density lipoprotein cholesterol .

Prevention & Lipids

Prevention and Lipids

L1 subspecialty spine topic for Prevention and Lipids (seeded from backend/data/cardiology_taxonomy.yaml).

Also called lipids, statins, PCSK9, primary prevention

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Cardiovascular disease is the leading cause of morbidity and death, with coronary heart disease accounting for 43% of deaths attributable to this condition in the US.1

Diagnosis and risk stratification

Risk stratification in primary prevention can utilize the PREVENT calculator for estimating cardiovascular disease risk.1 The 2025 guidelines from the US Department of Veterans Affairs and US Department of Defense removed previous recommendations against routine lipid monitoring and added coronary artery calcium testing as a risk refinement strategy.1 Nationally representative survey data indicated that 5.5% of adults aged 30 to 79 years had untreated low-density lipoprotein cholesterol below 70 mg/dL.2

Treatment

Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease.1 The US Preventive Services Task Force recommends statin use for adults aged 40 to 75 years without cardiovascular disease who have at least 1 risk factor and an estimated 10-year event risk of 10% or greater.2 For patients who are statin intolerant or require further lowering, ezetimibe reduces low-density lipoprotein cholesterol by 15%-20%.3 Proprotein convertase subtilisin/kexin type 9 inhibitors achieve profound reductions of 54%-74% when added to statins.3 Additional options include bempedoic acid for statin intolerance, the small interfering RNA inclisiran, and high dose icosapent ethyl.1

Open questions

Cardiovascular outcome data for newer agents like inclisiran remain lacking.1 Furthermore, emerging oral agents such as enlicitide decanoate are under investigation to address barriers related to subcutaneous administration.2

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.